On March 27, 2026, Autolus Therapeutics plc (Nasdaq: AUTL) announced its financial results for the fourth quarter and full year ended December 31, 2025. The company reported net product revenue of $23.3 million for Q4 2025 and $74.3 million for the full year, driven primarily by U.S. sales of its product AUCATZYL (obecabtagene autoleucel). Following a successful evaluation by the National Institute for Health and Care Excellence (NICE), AUCATZYL was launched in the UK in January 2026, marking a significant milestone for the company. Autolus anticipates that AUCATZYL will generate net product revenue of between $120 million to $135 million in 2026, with expectations of achieving a positive gross margin as patient numbers increase and operational efficiencies improve. The company also highlighted the positive clinical data from the ROCCA consortium, which confirmed a high level of clinical activity for AUCATZYL with a favorable safety profile. Furthermore, Autolus is advancing its pipeline with pivotal Phase 2 clinical trials for obe-cel in lupus nephritis and pediatric acute lymphoblastic leukemia (ALL), with initial data expected by the end of 2026. The company is committed to expanding its commercial footprint and enhancing its manufacturing capabilities to support growth in the coming years.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.